TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury
Copyright © 2016 by The American Association of Immunologists, Inc..
Invariant NKT (iNKT) cells represent a subset of innate-like T lymphocytes that function as orchestrators of hepatic inflammation underpinning liver damage. In this study, we demonstrate that TPL2, an MAP3 kinase that has mostly been appreciated for its physiological role in macrophage responses, is a signaling factor in CD3(+)NK1.1(+) iNKT cells and mediator of hepatic inflammation. Genetic ablation of TPL2 in the mouse ameliorates liver injury induced by Con A and impinges on hallmarks of NKT cell activation in the liver without affecting NKT cell development in the thymus. The pivotal role of TPL2 in iNKT cell functions is further endorsed by studies using the iNKT-specific ligand α-galactosylceramide, which causes mild hepatitis in the mouse in a TPL2-dependent manner, including production of the effector cytokines IL-4 and IFN-γ, accumulation of neutrophils and licensing and activation of other immune cell types in the liver. A TPL2 kinase inhibitor mirrors the effects of genetic ablation of TPL2 in vivo and uncovers ERK and Akt as the TPL2-regulated signaling pathways responsible for IL-4 and IFN-γ expression through the activation of the transcription factors JunB and NFAT. Collectively, these findings expand our understanding of the mechanisms of iNKT cell activation and suggest that modulation of TPL2 has the potential to minimize the severity of immune-driven liver diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
|---|---|
| Enthalten in: |
Journal of immunology (Baltimore, Md. : 1950) - 196(2016), 10 vom: 15. Mai, Seite 4298-310 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vyrla, Dimitra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.06.2017 Date Revised 29.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4049/jimmunol.1501609 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM259164836 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM259164836 | ||
| 003 | DE-627 | ||
| 005 | 20231224190608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4049/jimmunol.1501609 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0863.xml |
| 035 | |a (DE-627)NLM259164836 | ||
| 035 | |a (NLM)27053764 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vyrla, Dimitra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2017 | ||
| 500 | |a Date Revised 29.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 by The American Association of Immunologists, Inc. | ||
| 520 | |a Invariant NKT (iNKT) cells represent a subset of innate-like T lymphocytes that function as orchestrators of hepatic inflammation underpinning liver damage. In this study, we demonstrate that TPL2, an MAP3 kinase that has mostly been appreciated for its physiological role in macrophage responses, is a signaling factor in CD3(+)NK1.1(+) iNKT cells and mediator of hepatic inflammation. Genetic ablation of TPL2 in the mouse ameliorates liver injury induced by Con A and impinges on hallmarks of NKT cell activation in the liver without affecting NKT cell development in the thymus. The pivotal role of TPL2 in iNKT cell functions is further endorsed by studies using the iNKT-specific ligand α-galactosylceramide, which causes mild hepatitis in the mouse in a TPL2-dependent manner, including production of the effector cytokines IL-4 and IFN-γ, accumulation of neutrophils and licensing and activation of other immune cell types in the liver. A TPL2 kinase inhibitor mirrors the effects of genetic ablation of TPL2 in vivo and uncovers ERK and Akt as the TPL2-regulated signaling pathways responsible for IL-4 and IFN-γ expression through the activation of the transcription factors JunB and NFAT. Collectively, these findings expand our understanding of the mechanisms of iNKT cell activation and suggest that modulation of TPL2 has the potential to minimize the severity of immune-driven liver diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 650 | 7 | |a Galactosylceramides |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Mitogens |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a alpha-galactosylceramide |2 NLM | |
| 650 | 7 | |a Concanavalin A |2 NLM | |
| 650 | 7 | |a 11028-71-0 |2 NLM | |
| 650 | 7 | |a Interleukin-4 |2 NLM | |
| 650 | 7 | |a 207137-56-2 |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Extracellular Signal-Regulated MAP Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 650 | 7 | |a MAP Kinase Kinase Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.25 |2 NLM | |
| 650 | 7 | |a Map3k8 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.7.11.25 |2 NLM | |
| 700 | 1 | |a Nikolaidis, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Oakley, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Perugorria, Maria J |e verfasserin |4 aut | |
| 700 | 1 | |a Tsichlis, Philip N |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Derek A |e verfasserin |4 aut | |
| 700 | 1 | |a Eliopoulos, Aristides G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunology (Baltimore, Md. : 1950) |d 1945 |g 196(2016), 10 vom: 15. Mai, Seite 4298-310 |w (DE-627)NLM000018554 |x 1550-6606 |7 nnns |
| 773 | 1 | 8 | |g volume:196 |g year:2016 |g number:10 |g day:15 |g month:05 |g pages:4298-310 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4049/jimmunol.1501609 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 196 |j 2016 |e 10 |b 15 |c 05 |h 4298-310 | ||